Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 1
Submit an article Journal homepage
195
Views
0
CrossRef citations to date
0
Altmetric
Rosacea

Dose, duration, and cost: opportunities to improve use of long-term oral antibiotics for people with rosacea

Joanne S. RillDermatology Associates of Lancaster, Lancaster, PA, USA; View further author information
,
Hadar Lev-TovDepartment of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL, USA; View further author information
,
Guodong LiuDivision of Health Services Research, Department of Public Health Sciences, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA; View further author information
&
Joslyn S. KirbyDepartment of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USACorrespondence[email protected]
View further author information
Pages 63-67 | Received 26 Mar 2018, Accepted 30 Mar 2018, Published online: 07 May 2018

References

  • Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs. environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015;151:1213–1219.
  • Gerber PA, Buhren BA, Steinhoff M, et al. Rosacea: the cytokine and chemokine network. J Invest Dermatol Symp Proc. 2011;15:40–47.
  • Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92:234–240.
  • Tan J, Blume-Peytavi U, Ortonne JP, et al. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol. 2013;169:555–562.
  • Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93:18–28.
  • Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465–471.
  • Asai Y, Tan J, Baibergenova A, et al. Canadian clinical practice guidelines for rosacea. J Cutan Med Surg. 2016;20:432–445.
  • Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92:277–284.
  • Reinholz M, Tietze JK, Kilian K, et al. Rosacea – S1 guideline. JDDG. 2013;11:768–780. 768–779.
  • Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368:299–302.
  • Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93:134–138.
  • van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev. 2015;4:Cd003262.
  • Helwick C. Cost and drug utilization patterns associated with the management of rosacea. Am Health Drug Benefits. 2013;6:583–584.
  • Romanowicz M, Stephenson JJ, Del Rosso JQ, et al. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol. 2008;7:41–49.
  • Yentzer BA, Fleischer AB Jr. Changes in rosacea comorbidities and treatment utilization over time. J Drugs Dermatol. 2010;9:1402–1406.
  • Lumley T, Diehr P, Emerson S, et al. The importance of the normality assumption in large public health data sets. Annu Rev Public Health. 2002;23:151–169.
  • Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin. 2007;25:127–132.
  • U.S. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. In: U.S. Department of Health and Human Services, [Internet] ed2013. Available from: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
  • Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol. 2012;11:838–844.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.